InspireMD, Inc. (NSPR) Reports Q4 Loss, Tops Revenue Estimates

Company Performance - InspireMD, Inc. reported a quarterly loss of $0.19 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.20, but worse than the loss of $0.16 per share from the previous year, indicating a 19% increase in loss year-over-year [1] - The company posted revenues of $1.95 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 6.50% and showing a year-over-year increase from $1.76 million [2] - InspireMD has surpassed consensus EPS estimates two times and revenue estimates three times over the last four quarters [2] Stock Movement and Outlook - InspireMD shares have increased by approximately 6.1% since the beginning of the year, contrasting with the S&P 500's decline of 5.3% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.14 on revenues of $1.88 million, and for the current fiscal year, it is -$0.73 on revenues of $10.54 million [7] Industry Context - The Medical - Instruments industry, to which InspireMD belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - AngioDynamics, another company in the same industry, is expected to report a quarterly loss of $0.13 per share, reflecting an 18.8% year-over-year change, with revenues projected to be $70.58 million, down 6.1% from the previous year [9]